Two commonly prescribed cardiovascular medications were recalled by their manufacturers in early 2026 due to manufacturing defects that could reduce their effectiveness — creating a potential gap in protection for patients depending on these drugs to manage their cholesterol and cardiovascular disease risk.
The FDA classified both as Class II recalls — meaning the product involved "may cause temporary or medically reversible adverse health consequences" rather than posing an immediate life-threatening danger. In practice, this means the drugs may not work as effectively as they should, not that they are actively harmful to take.
